Guide Use of Tocilizumab for COVID-19 Based on New Data

March 2021

You’ll hear renewed interest in tocilizumab for COVID-19...based on new data suggesting it reduces mortality in some patients.

IL-6 inhibitors, such as tocilizumab (Actemra), sparked early interest in COVID-19 to block cytokines and reduce inflammation.

But trials haven’t consistently demonstrated a benefit.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote